CRISPR Therapeutics AG (CRSP) EBT Margin (2016 - 2026)

CRISPR Therapeutics AG has disclosed EBT Margin across 11 years of filings, most recently posting 8373.94% for Q1 2026.

• EBT Margin for Q1 2026 came in at 8373.94%, up 721994.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 1104.61% (up 104565.0% YoY), and the FY2025 annual result was 926.7%, up 81620.0% from the prior year.
• EBT Margin came in at 8373.94% for Q1 2026 at CRISPR Therapeutics AG, down from 55612.62% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 55612.62% in Q4 2025 to a low of 2000850.0% in Q4 2022.
• The 5-year median for EBT Margin is 14862.22% (2025), against an average of 148967.58%.
• Across the five-year window, EBT Margin slumped 199970208 bps in 2022 and soared 200089452 bps in 2023, its largest moves.
• CRISPR Therapeutics AG's EBT Margin stood at 2000850.0% in 2022, then surged by 100 bps to 44.52% in 2023, then surged by 2211 bps to 1029.07% in 2024, then soared by 5304 bps to 55612.62% in 2025, then plunged by 115 bps to 8373.94% in 2026.
• The last three EBT Margin figures came in at 8373.94% (Q1 2026), 55612.62% (Q4 2025), and 11903.49% (Q3 2025), per Business Quant data.